Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells

被引:22
作者
Yang, CM
Tsai, YJ
Pan, SL
Wu, WB
Wang, CC
Lee, YS
Lin, CC
Huang, SCM
Chiu, CT
机构
[1] Chang Gung Univ, Coll Med, Dept Pharmacol, Tao Yuan, Taiwan
[2] Chang Gung Univ, Coll Med, Grad Inst Clin Med, Tao Yuan, Taiwan
关键词
bradykinin receptor; inositol phosphate; Ca2+; pertussis toxin; vascular smooth muscle cells;
D O I
10.1016/S0898-6568(99)00056-X
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The pharmacological properties of bradykinin receptors were characterized in rat cultured vascular smooth muscle cells (VSMCs) using [H-3]-bradykinin as a ligand. Analysis of binding isotherms gave an apparent equilibrium dissociation constant (K-D) of 1.2 +/- 0.2 nM and a maximum receptor density (B-max) of 47.3 +/-: 4.4 fmol/mg protein. The specific binding of [H-3]-bradykinin to VSMCs was inhibited by the B-2 receptor-selective agonists (bradykinin and kallidin) and antagonists ([D-Arg(0), Hyp(3), Thi(5), D-Tic(7), Oic(8)]-bradykinin (Hoe 140) and [D-Arg(0), Hyp(3), Thi(5,8), D-Phe(7)]-bradykinin) with an order of potency as kallidin = bradykinin = Hoe 140 >, [D-Arg(0), Hyp(3), Thi(5,8), D-Phe(7)]-bradykinin, but not by a Bi receptor-selective agonist (des-Arg(9)-bradykinin) and antagonist ([Leu(8), des-Arg(9)]-bradykinin). Stimulation of VSMCs by bradykinin produced a concentration-dependent inositol phosphate (IP) accumulation, and initial transient peak of [Ca2+](i) with half-maximal responses (pECj(50)) were 7.53 and 7.69, respectively. B-2 receptor-selective antagonists (Hoe 140 and [D-Arg(0), Hyp(3), Thi(5,8) D-Phe(7)]-bradykinin) significantly antagonized the bradykinin-induced responses with pK(B) values of 8.3-8.7 and 7.2-7.9, respectively. Pretreatment of VSMCs with pertussis toxin (100 ng/ml, 24 h) did not. alter the bradykinin-induced inositol phosphate accumulation and [Ca2+](i) changes in VSMCs. Removal of external Ca2+ led to a significant attenuation of responses induced by bradykinin. Influx of external Ca2+ was required for the bradykinin-induced responses, since Ca2+-channel blockers, nifedipine, verapamil, and Ni2+, partially inhibited the bradykinin-induced IP accumulation and Ca2+ mobilization. These results demonstrate that bradykinin stimulates phosphoinositide hydrolysis and Ca2+ mobilization via a pertussis toxin-insensitive G-protein in rat VSMCs. Bradykinin B-2 receptors may be predominantly mediating IP accumulation and subsequently induction of Ca2+ mobilization may function as the transducing mechanism for bradykinin-stimulated contraction of vascular smooth muscle.
引用
收藏
页码:853 / 862
页数:10
相关论文
共 44 条
[1]  
BALMFORTH AJ, 1992, N-S ARCH PHARMACOL, V346, P303
[2]   INOSITOL PHOSPHATES AND CELL SIGNALING [J].
BERRIDGE, MJ ;
IRVINE, RF .
NATURE, 1989, 341 (6239) :197-205
[3]  
BHOOLA KD, 1992, PHARMACOL REV, V44, P1
[4]   MECHANISMS OF ACTION OF TRANSMITTERS AND OTHER SUBSTANCES ON SMOOTH-MUSCLE [J].
BOLTON, TB .
PHYSIOLOGICAL REVIEWS, 1979, 59 (03) :606-718
[5]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[6]   BRADYKININ AND ANGIOTENSIN-II - ACTIVATION OF PROTEIN-KINASE-C IN ARTERIAL SMOOTH-MUSCLE [J].
DIXON, BS ;
SHARMA, RV ;
DICKERSON, T ;
FORTUNE, J .
AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (05) :C1406-C1420
[7]   REGULATION OF THE FORMATION OF INOSITOL PHOSPHATES BY CALCIUM, GUANINE-NUCLEOTIDES AND ATP IN DIGITONIN-PERMEABILIZED BOVINE ADRENAL CHROMAFFIN CELLS [J].
EBERHARD, DA ;
HOLZ, RW .
BIOCHEMICAL JOURNAL, 1991, 279 :447-453
[8]   MOLECULAR-CLONING, FUNCTIONAL EXPRESSION AND PHARMACOLOGICAL CHARACTERIZATION OF A HUMAN BRADYKININ-B2 RECEPTOR GENE [J].
EGGERICKX, D ;
RASPE, E ;
BERTRAND, D ;
VASSART, G ;
PARMENTIER, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 187 (03) :1306-1313
[9]  
FARMER SG, 1989, MOL PHARMACOL, V36, P1
[10]   D-ARG[HYP3-THI5-D-TIC7-TIC8]-BRADYKININ, A POTENT ANTAGONIST OF SMOOTH-MUSCLE BK2 RECEPTORS AND BK3 RECEPTORS [J].
FARMER, SG ;
BURCH, RM ;
KYLE, DJ ;
MARTIN, JA ;
MEEKER, SN ;
TOGO, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (04) :785-787